Mixed Meal Tolerance Test Results from Revita-2, the First Randomized, Sham-Controlled, Double-Blind, Prospective, Multicenter Study of Duodenal Mucosal Resurfacing Safety and Efficacy in Patients with Sub-Optimally Controlled Type 2 Diabetes
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Revita Duodenal Mucosal Resurfacing (DMR) is a non-drug, minimally invasive, endoscopic procedure by thermal ablation of the submucosal duodenum performed in approximately 1hr in which data suggests improvements in glycemic and hepatic parameters in patients poorly controlled type-2 diabetes.
- REVITA-2 is the first randomized controlled trial evaluating the efficacy and safety of Revita DMR in patients with suboptimally controlled Type 2 Diabetes (T2D) with the primary endpoint showing that DMR significantly improved both glycemic control and liver fat content compared to Sham (previously presented). The data presented at ENDO 2020 meeting evaluated the results from mixed-meal tolerance tests in Revita-2 patients.
- DMR markedly improves glucose responses to a mixed meal challenge, primarily driven by a decrease in FPG, suggesting a primary effect on insulin resistance. Increases in C-peptide and reductions in glucagon levels suggest improvement in beta cell function in addition to improvements in hepatic insulin sensitivity and ratifies the position of the duodenum as both a culprit endocrine organ and therapeutic target for patients with T2D.
Presenting Author
David Hopkins, FRCP
Department of Diabetic Medicine
King’s College Hospital NHS Foundation Trust
David Hopkins is a consultant physician and diabetologist based in London. He is Institute Director and Clinical Academic Group lead for the Institute of Diabetes, Endocrinology and Obesity at King’s Health Partners, an academic health science centre comprising King’s College London, King’s College Hospital, Guy’s & St Thomas’ Hospitals and South London & Maudsley NHS trust. He is co-chair of the Council of Healthcare Professionals at Diabetes UK.
Author disclosures
David Hopkins has received honorarium for consultancy and/or speaker fees from Novo Nordisk, Sanofi, Astra Zeneca, Roche, Sunovion, Fractyl Laboratories Inc.
